Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: Potential use as a biomarker of ΔF508 cystic fibrosis transmembrane conductance regulator rescue

American Journal of Respiratory Cell and Molecular Biology

Volumn 43, Issue 5, 2010, Pages 607-616

  Pyle, Louise C ^d,f   Fulton, Jennifer C ^a   Sloane, Peter A ^a,f   Backer, Kyle ^a,f   Mazur, Marina ^a,f   Prasain, Jeevan ^c,f   Barnes, Stephen ^c,f   Clancy, J P ^b,f   Rowe, Steven M ^a,b,e,f  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Airway epithelia; Cystic fibrosis; Nasal potential difference; Short circuit current

Indexed keywords

APIGENIN; BIOCHANIN A; CATECHIN; COUMARIC ACID; COUMESTROL; CYCLIC AMP; DAIDZEIN; DIHYDRODAIDZEIN; EQUOL; FLAVONOID; FORMONONETIN; GENISTEIN; ISOPRENALINE; NARINGENIN; PUERARIN; QUERCETIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; BETA 2 ADRENERGIC RECEPTOR; BIOLOGICAL MARKER; CHLORIDE; MUTANT PROTEIN;

ANIMAL CELL; ANION TRANSPORT; ARTICLE; BETA ADRENERGIC STIMULATION; CELL SURFACE; CHLORIDE CONDUCTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; ELECTRIC POTENTIAL; GENETIC TRANSDUCTION; HUMAN; HYPERPOLARIZATION; LOW TEMPERATURE; MOUSE; NASAL POTENTIAL DIFFERENCE; NONHUMAN; NOSE MUCOSA; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RAT; RESPIRATORY EPITHELIUM; SHORT CIRCUIT CURRENT; THYROID CELL; ANIMAL; CELL MEMBRANE; CELL MEMBRANE POTENTIAL; CELL STRAIN 3T3; CHANNEL GATING; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; ION TRANSPORT; METABOLISM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE;

MUS; RATTUS;

ANIMALS; BIOLOGICAL MARKERS; CELL MEMBRANE; CHLORIDES; CYCLIC AMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; ION CHANNEL GATING; ION TRANSPORT; MEMBRANE POTENTIALS; MICE; MUTANT PROTEINS; NASAL MUCOSA; NIH 3T3 CELLS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; QUERCETIN; RATS; RECEPTORS, ADRENERGIC, BETA-2;

EID: 78149309127     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2009-0281OC     Document Type: Article

References (58)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001.
2. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992;358:761-764.
3. Egan ME, Glockner-Pagel J, Ambrose C, Cahill PA, Pappoe L, Balamuth N, Cho E, Canny S, Wagner CA, Geibel J, et al. Calcium-pump inhibitors induce functional surface expression of delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 2002;8:485-492. (Pubitemid 34546751)
4. Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glockner-Pagel J, Canny S, Du K, Lukacs GL, Caplan MJ. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004;304:600-602. (Pubitemid 38541921)
5. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1996;1:117-125. (Pubitemid 126670773)
6. Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, et al. Rescue of deltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006;290:L1117-L1130.
7. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, Verkman AS. Small-molecule correctors of defective deltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005;115:2564-2571. (Pubitemid 41266219)
8. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 1996;271:635-638. (Pubitemid 26034907)
9. Bebok Z, Venglarik CJ, Panczel Z, Jilling T, Kirk KL, Sorscher EJ. Activation of deltaF508 CFTR in an epithelial monolayer. Am J Physiol 1998;275:C599-C607. (Pubitemid 28390049)
10. Hwang TC, Wang F, Yang IC, Reenstra WW. Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol 1997;273:C988-C998. (Pubitemid 27422179)
11. Wang F, Zeltwanger S, Yang IC, Nairn AC, Hwang TC. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects. J Gen Physiol 1998;111:477-490. (Pubitemid 28136466)
12. Al-Nakkash L, Hwang TC. Activation of wild-type and deltaF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms. Pflugers Arch 1999;437:553-561. (Pubitemid 29110907)
13. Bebok Z, Collawn JF, Wakefield J, Parker W, Li Y, Varga K, Sorscher EJ, Clancy JP. Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o2 airway epithelial monolayers. J Physiol 2005;569:601-615. (Pubitemid 41830125)
14. Hentchel-Franks K, Lozano D, Eubanks-Tarn V, Cobb B, Fan L, Oster R, Sorscher E, Clancy JP. Activation of airway Cl- secretion in human subjects by adenosine. Am J Respir Cell Mol Biol 2004;31:140-146. (Pubitemid 39095443)
15. Galietta LJ, Springsteel MF, Eda M, Niedzinski EJ, By K, Haddadin MJ, Kurth MJ, Nantz MH, Verkman AS. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem 2001;276:19723-19728. (Pubitemid 37411030)
16. Illek B, Lizarzaburu ME, Lee V, Nantz MH, Kurth MJ, Fischer H. Structural determinants for activation and block of CFTR-mediated chloride currents by apigenin. Am J Physiol Cell Physiol 2000;279:C1838-C1846.
17. Springsteel MF, Galietta LJ, Ma T, By K, Berger GO, Yang H, Dicus CW, Choung W, Quan C, Shelat AA, et al. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorg Med Chem 2003;11:4113-4120. (Pubitemid 36970138)
18. Fulton JC, Pyle LC, Fan L, Fortenberry J, Sthanam M, Clancy JP, Rowe SM. The flavonoid quercetin activates wild-type and dF508 CFTR at concentrations suitable for in vivo detection of rescued protein. Pediatr Pulmonol Suppl 2008;43:249. (abstract).
19. Fulton JC, Fortenberry JA, Fan L, Sthanam M, Clancy JP, Rowe SM. The flavonoid quercetin activates wild type and mutant CFTR at concentrations suitable for in vivo detection of rescued protein. Am J Respir Crit Care Med 2008;177:A457. (abstract).
20. Rowe SM, Varga K, Rab A, Bebok Z, Byram K, Li Y, Sorscher EJ, Clancy JP. Restoration of w1282x CFTR activity by enhanced expression. Am J Respir Cell Mol Biol 2007;37:347-356. (Pubitemid 350067614)
21. Pyle L, Ehrhardt A, Nowotarski K, Rowe SM, Sorscher EJ. The role of R-domain phosphorylation in CFTR activation by potentiators. North American Cystic Fibrosis Foundation AnnualMeeting. Denver, CO; 2006.
22. Kelley TJ, Thomas K, Milgram LJ, Drumm ML. In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant deltaF508 in murine nasal epithelium. Proc Natl Acad Sci USA 1997;94:2604-2608.
23. Cobb BR, Ruiz F, King CM, Fortenberry J, Greer H, Kovacs T, Sorscher EJ, Clancy JPA. (2) Adenosine receptors regulate CFTR through PKA and PLA(2). Am J Physiol Lung Cell Mol Physiol 2002;282:L12-L25.
24. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995;6:445-455.
25. Schmidt A, Hughes LK, Cai Z, Mendes F, Li H, Sheppard DN, Amaral MD. Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator. Br J Pharmacol 2008;153:1311-1323.
26. Illek B, Fischer H. Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. Am J Physiol 1998;275:L902-L910.
27. Mall M, Wissner A, Seydewitz HH, Hubner M, Kuehr J, Brandis M, Greger R, Kunzelmann K. Effect of genistein on native epithelial tissue from normal individuals and CF patients and on ion channels expressed in Xenopus oocytes. Br J Pharmacol 2000;130:1884-1892.
28. Wang L, Tu YC, Lian TW, Hung JT, Yen JH, Wu MJ. Distinctive antioxidant and antiinflammatory effects of flavonols. J Agric Food Chem 2006;54:9798-9804.
29. Mamani-Matsuda M, Kauss T, Al-Kharrat A, Rambert J, Fawaz F, Thiolat D, Moynet D, Coves S, Malvy D, Mossalayi MD. Therapeutic and preventive properties of quercetin in experimental arthritis correlate with decreased macrophage inflammatory mediators. Biochem Pharmacol 2006;72:1304-1310.
30. Jackson JK, Higo T, Hunter WL, Burt HM. The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflamm Res 2006;55:168-175.
31. Hung H. Dietary quercetin inhibits proliferation of lung carcinoma cells. Forum Nutr 2007;60:146-157.
32. Jalili T, Carlstrom J, Kim S, Freeman D, Jin H, Wu TC, Litwin SE, David Symons J. Quercetin-supplemented diets lower blood pressure and attenuate cardiac hypertrophy in rats with aortic constriction. J Cardiovasc Pharmacol 2006;47:531-541.
33. Pedemonte N, Sondo E, Galietta LJ. Evaluation of potentiators and correctors for the functional rescue of dF508 CFTR protein. Pediatr Pulmonol Suppl 2007;42:A268.
34. Chan AL, Huang HL, Chien HC, Chen CM, Lin CN, Ko WC. Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [(3) H]-rolipram binding in guinea pig tissues. Invest New Drugs 2008;26:417-424.
35. Ko WC, Shih CM, Lai YH, Chen JH, Huang HL. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships. Biochem Pharmacol 2004;68:2087-2094.
36. Moran O, Galietta LJ, Zegarra-Moran O. Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell Mol Life Sci 2005;62:446-460.
37. Al-Nakkash L, Hu S, Li M, Hwang TC. A common mechanism for cystic fibrosis transmembrane conductance regulator protein activation by genistein and benzimidazolone analogs. J Pharmacol Exp Ther 2001;296:464-472.
38. Weinreich F, Wood PG, Riordan JR, Nagel G. Direct action of genistein on CFTR. Pflugers Arch 1997;434:484-491.
39. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, Pedemonte N, et al. Nanomolar affinity small molecule correctors of defective delta F508-CFTR chloride channel gating. J Biol Chem 2003;278:35079-35085.
40. Standaert TA, Boitano L, Emerson J, Milgram LJ, Konstan MW, Hunter J, Berclaz PY, Brass L, Zeitlin PL, Hammond K, et al. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol 2004;37:385-392.
41. Schuier M, Sies H, Illek B, Fischer H. Cocoa-related flavonoids inhibit CFTR-mediated chloride transport across t84 human colon epithelia. J Nutr 2005;135:2320-2325.
42. Lim M, McKenzie K, Floyd AD, Kwon E, Zeitlin PL. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol 2004;31:351-357.
43. Varga K, Jurkuvenaite A, Wakefield J, Hong JS, Guimbellot JS, Venglarik CJ, Niraj A, Mazur M, Sorscher EJ, Collawn JF, et al. Efficient intracellular processing of the endogenous cystic fibrosis transmembrane conductance regulator in epithelial cell lines. J Biol Chem 2004;279:22578-22584.
44. Swiatecka-Urban A, Brown A, Moreau-Marquis S, Renuka J, Coutermarsh B, Barnaby R, Karlson KH, Flotte TR, Fukuda M, Langford GM, et al. The short apical membrane half-life of rescued fdeltagF508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of fdeltagF508-CFTR in polarized human airway epithelial cells. J Biol Chem 2005;280:36762-36772.
45. Hansen RK, Oesterreich S, Lemieux P, Sarge KD, Fuqua SA. Quercetin inhibits heat shock protein induction but not heat shock factor DNA-binding in human breast carcinoma cells. Biochem Biophys Res Commun 1997;239:851-856.
46. Wang F, Zeltwanger S, Hu S, Hwang TC. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels. J Physiol 2000;524:637-648.
47. Wang W, Bernard K, Li G, Kirk KL. Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J Biol Chem 2007;282:4533-4544.
48. Derichs N, Mekus F, Bronsveld I, Bijman J, Veeze HJ, von der Hardt H, Tummler B, Ballmann M. Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients. Pediatr Res 2004;55:69-75.
49. Accurso F, Rowe SM, Durie PR, Konstan MW, Dunitz J, Hornick DB, Sagel SD, Boyle MP, Uluer AZ, D. U, et al. Interim results of Phase 2a study of VX-770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. European CF Meeting 2008.
50. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002;22:19-34.
51. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996;2:659-668.
52. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007;45:2179-2205.
53. Matsuo M, Sasaki N, Saga K, Kaneko T. Cytotoxicity of flavonoids toward cultured normal human cells. Biol Pharm Bull 2005;28:253-259.
54. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with Category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999;54:960-963.
55. Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T. Quercetin reduces blood pressure in hypertensive subjects. J Nutr 2007;137:2405-2411.
56. Morino K, Matsukara N, Kawachi T, Ohgaki H, Sugimura T, Hirono I. Carcinogenicity test of quercetin and rutin in golden hamsters by oral administration. Carcinogenesis 1982;3:93-97.
57. Ito N, Hagiwara A, Tamano S, Kagawa M, Shibata M, Kurata Y, Fukushima S. Lack of carcinogenicity of quercetin in f344/DUCRJ rats. Jpn J Cancer Res 1989;80:317-325.
58. Hard GC, Seely JC, Betz LJ, Hayashi SM. Re-evaluation of the kidney tumors and renal histopathology occurring in a 2-year rat carcinogenicity bioassay of quercetin. Food Chem Toxicol 2007;45:600-608.